With a net profit of 14 billion yuan in the first quarter of 2022, Jiu’an Medical (002432.SZ) has once again become the focus of the market.
On the evening of April 29, Jiu’an Medical released its 2021 annual report and 2022 first quarter report. The company’s net profit last year was 909 million yuan, a year-on-year increase of 274.96%; the first quarter of this year’s net profit was 14.312 billion yuan, a year-on-year increase of 37527.35%.
When a reporter from “Daily Economic News” interviewed Liu Yi, chairman of Jiu’an Medical in March this year, the other party said that the core strategy of Jiu’an Medical has not changed, but “after this epidemic”, there are more funds on hand. In the future, the abundant cash brought by the new crown self-test kit will mainly be invested in two core strategies, namely, the promotion of the company’s new diabetes diagnosis and treatment “O+O” model in China and the United States, and the launch of extremely cost-effective products on new retail platforms.
According to the announcement of Jiu’an Medical on the evening of April 29, the board of directors agreed that the company will use idle self-owned funds of no more than 9.5 billion yuan or equivalent foreign currency to purchase financial institutions such as banks and brokerages with high security, low risk and good liquidity. issued investment products. The matter still needs to be submitted to the 2021 Annual General Meeting for consideration.
Copyright Notice
1This article is an original work of “Daily Economic News”.
2
Without the authorization of “Daily Economic News”, it may not be used in any way, including but not limited to reprinting, excerpting, copying or creating mirror images, etc. Violators will be held accountable.
3Copyright cooperation telephone: 021-60900099.